[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 30, Amgen Inc. (NASDAQ:AMGN) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers. The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint. The Bemarituzumab plus chemotherapy significantly improved […]",
    "url": "https://finnhub.io/api/news?id=8977627e29d45ae4c3925c6802e22ae2e2a89fe0b93f01618a63041124944b13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751787344,
      "headline": "Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab",
      "id": 135773784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 30, Amgen Inc. (NASDAQ:AMGN) announced positive topline results for an important phase 3 study of Bemarituzumab for certain stomach cancers. The company announced that the Phase 3 FORTITUDE-101 trial met its primary endpoint. The Bemarituzumab plus chemotherapy significantly improved […]",
      "url": "https://finnhub.io/api/news?id=8977627e29d45ae4c3925c6802e22ae2e2a89fe0b93f01618a63041124944b13"
    }
  }
]